Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in

Wing-Kee Lee1, Thévenod Frank1

  • 1Institute for Physiology, Pathophysiology and Toxicology, ZBAF, Witten/Herdecke University, Witten 58453, Germany.

Insights

Developmental signaling pathways reactivated in cancer drive multidrug resistance (MDR) by upregulating the ABCB1 transporter. This impacts tumor progression, metastasis, and cancer stemness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Multidrug resistance (MDR) in cancer is linked to transporter expression.
  • ABCB1 (P-glycoprotein) mediates drug efflux and inhibits apoptosis.
  • Tumors contain diverse cell populations with MDR phenotypes.

Purpose of the Study:

  • To review the role of developmental signaling pathways in ABCB1 transcriptional regulation.
  • To explore how these pathways contribute to MDR in cancer.

Main Methods:

  • Literature review focusing on developmental signaling pathways and ABCB1.
  • Analysis of canonical and non-canonical pathway contributions to MDR.

Main Results:

  • Developmental pathways (Hedgehog, Notch, Wnt, TGFβ, PITX2) are reactivated in cancer.
  • These pathways transcriptionally upregulate ABCB1, conferring MDR.
  • ABCB1 is implicated in cancer stemness and is a marker for it.

Conclusions:

  • Canonical and non-canonical developmental signaling pathways are key regulators of ABCB1 expression in cancer.
  • Understanding these pathways offers insights into overcoming MDR and targeting cancer stem cells.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K